Interferon: The Dawn of Recombinant Protein Drugs
Forty years of Interferon I wish to dedicate this short introduction to the memory of Alick Isaacs (1921-1967), and to that of Sir Christopher Andrewes (1896-1988). Let us go back more than 40 years. In 1956 Isaacs was in charge of the Wodd Influenza Centre. Andrewes was head of the division of bac­ teriology and virology, and deputy director of the National Institute for Medical Research in London. When researchers are faced with a seemingly new phenomenon, ex­ planations are easy to come by. These explanations fall into two broad categories: the phenomenon in question is either due to something or to the lack of something. I apologize for the primitive way in which I ex­ press this, but I am going to give three examples, scattered over 100 years, of what I mean. First example: in 1880 the great French microbiologist Louis Pas­ teur was involved in work on chicken cholera. He was struck by the following observation: if a suitable chicken broth was inoculated with the bacterium, the organism grew profusely and the liquid became tur­ bid. If he now freed the fluid, by sedimentation or filtration, from the bulk of the organisms and re-inoculated it with the same bacterium, no growth occurred.
1111478897
Interferon: The Dawn of Recombinant Protein Drugs
Forty years of Interferon I wish to dedicate this short introduction to the memory of Alick Isaacs (1921-1967), and to that of Sir Christopher Andrewes (1896-1988). Let us go back more than 40 years. In 1956 Isaacs was in charge of the Wodd Influenza Centre. Andrewes was head of the division of bac­ teriology and virology, and deputy director of the National Institute for Medical Research in London. When researchers are faced with a seemingly new phenomenon, ex­ planations are easy to come by. These explanations fall into two broad categories: the phenomenon in question is either due to something or to the lack of something. I apologize for the primitive way in which I ex­ press this, but I am going to give three examples, scattered over 100 years, of what I mean. First example: in 1880 the great French microbiologist Louis Pas­ teur was involved in work on chicken cholera. He was struck by the following observation: if a suitable chicken broth was inoculated with the bacterium, the organism grew profusely and the liquid became tur­ bid. If he now freed the fluid, by sedimentation or filtration, from the bulk of the organisms and re-inoculated it with the same bacterium, no growth occurred.
109.99 In Stock
Interferon: The Dawn of Recombinant Protein Drugs

Interferon: The Dawn of Recombinant Protein Drugs

Interferon: The Dawn of Recombinant Protein Drugs

Interferon: The Dawn of Recombinant Protein Drugs

Paperback(Softcover reprint of the original 1st ed. 1999)

$109.99 
  • SHIP THIS ITEM
    In stock. Ships in 6-10 days.
  • PICK UP IN STORE

    Your local store may have stock of this item.

Related collections and offers


Overview

Forty years of Interferon I wish to dedicate this short introduction to the memory of Alick Isaacs (1921-1967), and to that of Sir Christopher Andrewes (1896-1988). Let us go back more than 40 years. In 1956 Isaacs was in charge of the Wodd Influenza Centre. Andrewes was head of the division of bac­ teriology and virology, and deputy director of the National Institute for Medical Research in London. When researchers are faced with a seemingly new phenomenon, ex­ planations are easy to come by. These explanations fall into two broad categories: the phenomenon in question is either due to something or to the lack of something. I apologize for the primitive way in which I ex­ press this, but I am going to give three examples, scattered over 100 years, of what I mean. First example: in 1880 the great French microbiologist Louis Pas­ teur was involved in work on chicken cholera. He was struck by the following observation: if a suitable chicken broth was inoculated with the bacterium, the organism grew profusely and the liquid became tur­ bid. If he now freed the fluid, by sedimentation or filtration, from the bulk of the organisms and re-inoculated it with the same bacterium, no growth occurred.

Product Details

ISBN-13: 9783662037898
Publisher: Springer Berlin Heidelberg
Publication date: 10/03/2013
Series: Ernst Schering Foundation Symposium Proceedings , #5
Edition description: Softcover reprint of the original 1st ed. 1999
Pages: 138
Product dimensions: 5.83(w) x 8.27(h) x (d)

Table of Contents

1 Is There Life Without Interferon?.- 2 What Constitutes Therapeutic Success? The Interferons (1978–1998).- 3 The Prehistory and History of the Uses of Interleukin-2 in Cancer Therapy.- 4 Interferon-β: From Pass Interference to Cytokine Networking.- 5 A Biosemiotic View of Interferon: Toward a Biology of Really Living Organisms.- 6 The Clinical and Social Impact of Beta Interferon: the First Approved Therapy in Multiple Sclerosis.- 7 Closing Discussion.- Previous Volumes Published in this Series.
From the B&N Reads Blog

Customer Reviews